2006
E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer
Lin J, Dinney C, Grossman H, Jhamb M, Zhu Y, Spitz, Wu X. E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer. Clinical Genetics 2006, 70: 240-245. PMID: 16922727, DOI: 10.1111/j.1399-0004.2006.00666.x.Peer-Reviewed Original ResearchConceptsSuperficial bladder cancerBladder cancer recurrenceBladder cancerCancer recurrencePromoter polymorphismHazard ratioCaucasian patientsMedian recurrence-free survivalMedical chart reviewRecurrence-free survivalRisk of recurrencePeripheral blood lymphocytesProportional hazards modelHomozygous CC genotypeChart reviewDisease recurrenceSmoking statusTumor recurrenceTumor stageBlood lymphocytesClinical dataCC genotypeHazards modelPatientsRecurrence risk
2004
Methyl‐CpG‐binding domain 2
Zhu Y, Spitz M, Zhang H, Grossman H, Frazier M, Wu X. Methyl‐CpG‐binding domain 2. Cancer 2004, 100: 1853-1858. PMID: 15112265, DOI: 10.1002/cncr.20199.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceCase-Control StudiesDNA MethylationDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansLogistic ModelsMaleMolecular Sequence DataOdds RatioProbabilityPrognosisPromoter Regions, GeneticReference ValuesReverse Transcriptase Polymerase Chain ReactionRisk FactorsRNA, MessengerSensitivity and SpecificityUrinary Bladder NeoplasmsConceptsMBD2 expressionCarcinoma riskCurrent case-control studyReverse transcription polymerase chain reaction assaysCase-control studyPeripheral blood lymphocytesQuantitative reverse transcription-polymerase chain reaction assaysTranscription-polymerase chain reaction assaysMessenger RNA expressionReal-time quantitative reverse transcription-polymerase chain reaction assaysControl patientsLight smokersCase patientsHeavy smokersUnderlying molecular mechanismsTumor tissue typesBlood lymphocytesChain reaction assaysProtective effectProtective roleQuartile distributionDomain 2 proteinOlder individualsTumor developmentYoung individuals
2003
Telomere Dysfunction: A Potential Cancer Predisposition Factor
Wu X, Amos C, Zhu Y, Zhao H, Grossman B, Shay J, Luo S, Hong W, Spitz M. Telomere Dysfunction: A Potential Cancer Predisposition Factor. Journal Of The National Cancer Institute 2003, 95: 1211-1218. PMID: 12928346, DOI: 10.1093/jnci/djg011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlotting, SouthernCarcinoma, Renal CellCase-Control StudiesDNA DamageDNA RepairDNA, NeoplasmFemaleFlow CytometryGenetic Predisposition to DiseaseHead and Neck NeoplasmsHumansIn Situ Hybridization, FluorescenceKidney NeoplasmsLung NeoplasmsLymphocytesMaleMiddle AgedNeoplasmsOdds RatioRisk AssessmentRisk FactorsSmokingTelomereUrinary Bladder NeoplasmsConceptsControl subjectsTelomere lengthNeck cancerOdds ratioCancer riskShort telomeresOngoing case-control studyPercent of patientsRenal cell cancerCase-control studyPeripheral blood lymphocytesLongest quartileCase patientsCell cancerSmoking statusDisease characteristicsBladder cancerBlood lymphocytesStratified analysisGenetic instabilityHuman bladderRenal cellsStudy participantsCancerPredisposition factors
2002
A case‐control analysis of lymphocytic chromosome 9 aberrations in lung cancer
Zhu Y, Spitz M, Strom S, Tomlinson G, Amos C, Minna J, Wu X. A case‐control analysis of lymphocytic chromosome 9 aberrations in lung cancer. International Journal Of Cancer 2002, 102: 536-540. PMID: 12432559, DOI: 10.1002/ijc.10762.Peer-Reviewed Original ResearchConceptsPeripheral blood lymphocytesChromosome 9 aberrationsLung cancerOdds ratioFamily historyPrimary lung tumorsLung cancer casesElevated odds ratiosCase-control analysisLung carcinoma specimensLung cancer predispositionFamily history analysisFrequent genetic changesEpidemiologic profileBlood lymphocytesLung tumorigenesisLung tumorsCancer casesCarcinoma specimensChromosome 9 abnormalitiesControl individualsCancerCytogenetic aberrationsFamilial aggregationChromosomal alterationsBPDE‐induced lymphocytic 3p21.3 aberrations may predict head and neck carcinoma risk
Zhu Y, Spitz M, Zheng Y, Hong W, Wu X. BPDE‐induced lymphocytic 3p21.3 aberrations may predict head and neck carcinoma risk. Cancer 2002, 95: 563-568. PMID: 12209748, DOI: 10.1002/cncr.10689.Peer-Reviewed Original ResearchMeSH Keywords7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxideAgedCarcinogensCarcinoma, Squamous CellChromosome AberrationsChromosomes, Human, Pair 3FemaleGenetic Predisposition to DiseaseGenetic TestingHead and Neck NeoplasmsHumansIn Situ Hybridization, FluorescenceLymphocytesMaleMiddle AgedPredictive Value of TestsConceptsPeripheral blood lymphocytesIndividual genetic susceptibilityGenetic susceptibilityTobacco carcinogensNeck squamous cell carcinomaNeck carcinoma riskSquamous cell carcinomaChromosomal aberrationsTobacco smoke constituentsDose-response relationshipTobacco exposureSpecific molecular targetsCell carcinomaHNSCC riskBlood lymphocytesRisk factorsOdds ratioCarcinoma riskPBL culturesCutoff pointLymphocytic cellsHNSCCBPDE sensitivityMolecular targetsSmoke constituents